P
Pablo Tamayo
Researcher at University of California, San Diego
Publications - 185
Citations - 117545
Pablo Tamayo is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 72, co-authored 177 publications receiving 97318 citations. Previous affiliations of Pablo Tamayo include University of California, Berkeley & Harvard University.
Papers
More filters
A resampling-based method for class discovery and visualization of gene expression microarray data
TL;DR: A new methodology of class discovery and clustering validation tailored to the task of analyzing gene expression data is presented and in conjunction with resampling techniques, it provides for a method to represent the consensus across multiple runs of a clustering algorithm and to assess the stability of the discovered clusters.
Journal ArticleDOI
Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy
Victoria Wu,Huwate Yeerna,Nijiro Nohata,Joshua Chiou,Olivier Harismendy,Francesco Raimondi,Asuka Inoue,Robert B. Russell,Pablo Tamayo,J. Silvio Gutkind +9 more
TL;DR: A comprehensive analysis of GPCR gene expression, copy number variation, and mutational signatures in 33 cancer types is presented and highlights the emerging role of G PCRs as part of oncocrine networks promoting tumor growth, dissemination, and immune evasion.
Journal ArticleDOI
Integrative radiogenomic profiling of squamous cell lung cancer
Mohamed E. Abazeed,Drew J. Adams,Kristen E. Hurov,Pablo Tamayo,Chad J. Creighton,Dmitriy Sonkin,Andrew O. Giacomelli,Charles Du,Daniel F. Fries,Kwok-Kin Wong,Jill P. Mesirov,Jay S. Loeffler,Stuart L. Schreiber,Peter S. Hammerman,Matthew Meyerson +14 more
TL;DR: The development of a high-throughput platform for measuring radiation survival in vitro and its validation in comparison with conventional clonogenic radiation survival analysis is reported and pathways implicated in cell survival, genotoxic stress, detoxification, and innate and adaptive immunity are identified as key correlates of radiation sensitivity.
Journal ArticleDOI
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Hee-Bum Kang,Jun Fan,Ruiting Lin,Shannon Elf,Quanjiang Ji,Liang Zhao,Lingtao Jin,Jae Ho Seo,Changliang Shan,Jack L. Arbiser,Jack L. Arbiser,Cynthia Cohen,Daniel J. Brat,Henry M. Miziorko,Eunhee Kim,Omar Abdel-Wahab,Taha Merghoub,Stefan Fröhling,Claudia Scholl,Pablo Tamayo,David A. Barbie,Lu Zhou,Brian Pollack,Brian Pollack,Kevin E. Fisher,Ragini R. Kudchadkar,David H. Lawson,Gabriel Sica,Michael R. Rossi,Sagar Lonial,Hanna Jean Khoury,Fadlo R. Khuri,Benjamin H. Lee,Titus J. Boggon,Chuan He,Sumin Kang,Jing Chen +36 more
TL;DR: A mutation-specific mechanism by which oncogenic BRAF V600E "rewires" metabolic and cell signaling networks and signals through the Oct-1-HMGCL-acetoacetate axis to selectively promote BRAFV600E-dependent tumor development is revealed.
Journal ArticleDOI
An expanded universe of cancer targets.
William C. Hahn,Joel S. Bader,Theodore P. Braun,Andrea Califano,Paul A. Clemons,Brian J. Druker,Andrew J. Ewald,Haian Fu,Subhashini Jagu,Christopher J. Kemp,William Kim,Calvin J. Kuo,Michael T. McManus,Gordon B. Mills,Xiulei Mo,Nidhi Sahni,Stuart L. Schreiber,Jessica A. Talamas,Pablo Tamayo,Jeffrey W. Tyner,Bridget K. Wagner,William A. Weiss,Daniela S. Gerhard,Vlado Dančík,Shubhroz Gill,Bruce K. Hua,Tanaz Sharifnia,Vasanthi S. Viswanathan,Yilong Zou,Filemon S. Dela Cruz,Andrew L. Kung,Brent R. Stockwell,Jesse S. Boehm,Josh Dempster,Robert T. Manguso,Francisca Vazquez,Lee Cooper,Yuhong Du,Andrey A. Ivanov,Sagar Lonial,Carlos S. Moreno,Qiankun Niu,Taofeek K. Owonikoko,Suresh S. Ramalingam,Matthew A. Reyna,Wei Zhou,Carla Grandori,Ilya Shmulevich,Elizabeth M. Swisher,Jitong Cai,Issac S. Chan,Matthew Dunworth,Yuchen Ge,Dan Georgess,Eloise M. Grasset,Elodie Henriet,Hildur Knutsdottir,Michael G. Lerner,Veena Padmanaban,Matthew C. Perrone,Yasir Suhail,Yohannes Tsehay,Manisha Warrier,Quin Morrow,Tamilla Nechiporuk,Nicola Long,Jennifer Saultz,Andy Kaempf,Jessica Minnier,Cristina E. Tognon,Stephen E. Kurtz,Anupriya Agarwal,Jordana Brown,Kevin Watanabe-Smith,Tania Q. Vu,Thomas Jacob,Yunqi Yan,Bridget Robinson,Evan F. Lind,Yoko Kosaka,Emek Demir,Joseph Estabrook,Michael Grzadkowski,Olga Nikolova,Ken Chen,Ben Deneen,Han Liang,Michael C. Bassik,Asmita Bhattacharya,Kevin C. Brennan,Christina Curtis,Olivier Gevaert,Hanlee P. Ji,Kasper Karlsson,Kremena Karagyozova,Yuan-Hung Lo,Katherine N. Liu,Michitaka Nakano,Anuja Sathe,Amber R. Smith,Kaitlyn Spees,Wing Hing Wong,Kanako Yuki,Matt Hangauer,Dan S. Kaufman,Allan Balmain,Saumya R. Bollam,Wei-Ching Chen,Qi-Wen Fan,Kelly Kersten,Matthew F. Krummel,Yun Rose Li,Marie Menard,Nicole Nasholm,Christin Schmidt,Nina K. Serwas,Hiroyuki Yoda,Alan Ashworth,Sourav Bandyopadhyay,Trevor Bivona,Gabriel Eades,Stefan Oberlin,Neil Tay,Yuhao Wang,Jonathan S. Weissman +124 more
TL;DR: A framework is described for this expanded list of cancer targets, providing novel opportunities for clinical translation and indicating that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes.